Pembrolizumab for the treatment of advanced salivary gland carcinoma

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 41, Issue 11, 2018, Pages 1083-1088

  Cohen, Roger B ^a   Delord, Jean Pierre ^b   Doi, Toshihiko ^f   Piha Paul, Sarina A ^g   Liu, Stephen V ^h   Gilbert, Jill ⁱ   Algazi, Alain P ^j   Damian, Silvia ^k   Hong, Ruey Long ^l   Le Tourneau, Christophe ^c,d   Day, Daphne ^m,n   Varga, Andrea ^e   Elez, Elena ^o   Wallmark, John ^p   Saraf, Sanatan ^q   Thanigaimani, Pradeep ^q   Cheng, Jonathan ^q   Keam, Bhumsuk ^a,r  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b INSTITUT CLAUDIUS REGAUD   (France)

^c U900 INSERM Research Unit   (United States)

^d INSTITUT CURIE   (France)

^e INSTITUT GUSTAVE ROUSSY   (France)

^f NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^g UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^h GEORGETOWN UNIVERSITY HOSPITAL   (United States)

ⁱ VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j UNIVERSITY OF CALIFORNIA   (United States)

^k NATIONAL CANCER INSTITUTE   (Italy)

^l NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^m PRINCESS MARGARET HOSPITAL   (Canada)

ⁿ ONTARIO INSTITUTE FOR CANCER RESEARCH   (Canada)

^o VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

^p Maryland Oncology Hematology PA   (United States)

^q MERCK RESEARCH LABORATORIES   (United States)

^r Seoul National University Hospital   (South Korea)

more..

Author keywords

Anti PD 1; Immunotherapy; Pembrolizumab; Salivary gland cancer

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1;

ACNE; ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTHRALGIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BILIRUBIN BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; CONFERENCE PAPER; DECREASED APPETITE; DIARRHEA; DRUG FATALITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOLLOW UP; HEPATITIS; HUMAN; HYPOTHYROIDISM; INTERSTITIAL LUNG DISEASE; MALE; MULTICENTER STUDY; MYALGIA; NAUSEA; OPEN STUDY; PATIENT SAFETY; PHASE 1 CLINICAL TRIAL; PRURITUS; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; SALIVARY GLAND CARCINOMA; SIDE EFFECT; TREATMENT RESPONSE TIME;

EID: 85051226841     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0000000000000429     Document Type: Conference Paper

References (22)

1. Laurie SA, Licitra L. Systemic therapy in the palliative management of advanced salivary gland cancers. J Clin Oncol. 2006;24: 2673-2678.
2. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN guidelines): head and neck cancers (Version 2.2017). 2017. Available at: https://www.nccn.org/pro fessionals/physiciangls/pdf/head-and-neck.pdf. Accessed January 23, 2018.
3. Sung MW, Kim KH, Kim JW, et al. Clinicopathologic predictors and impact of distant metastasis from adenoid cystic carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg. 2003;129: 1193-1197.
4. Lagha A, Chraiet N, Ayadi M, et al. Systemic therapy in the management of metastatic or advanced salivary gland cancers. Head Neck Oncol. 2012;4:19.
5. Jeng YM, Lin CY, Hsu HC. Expression of the c-kit protein is associated with certain subtypes of salivary gland carcinoma. Cancer Lett. 2000;154:107-111.
6. Dodd RL, Slevin NJ. Salivary gland adenoid cystic carcinoma: a review of chemotherapy and molecular therapies. Oral Oncol. 2006;42:759-769.
7. Glisson B, Colevas AD, Haddad R, et al. HER2 expression in salivary gland carcinomas: dependence on histological subtype. Clin Cancer Res. 2004;10:944-946.
8. Jeannon JP, Soames JV, Bell H, et al. Immunohistochemical detection of oestrogen and progesterone receptors in salivary tumours. Clin Otolaryngol Allied Sci. 1999;24:52-54.
9. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252-264.
10. Iwai Y, Ishida M, Tanaka Y, et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA. 2002;99:12293-12297.
11. Mukaigawa T, Hayashi R, Hashimoto K, et al. Programmed death ligand-1 expression is associated with poor disease free survival in salivary gland carcinomas. J Surg Oncol. 2016;114:36-43.
12. Yearley J, Gibson G, Yu N, et al. PD-L2 expression in human tumors: relevance to anti-PD-1 therapy in cancer. Clin Cancer Res. 2017;23:3158-3167.
13. Sridharan V, Gjini E, Liao X, et al. Immune profiling of adenoid cystic carcinoma: PD-L2 expression and associations with tumor infiltrating lymphocytes. Cancer Immunol Res. 2016;4:679-687.
14. Merck Sharp &Dohme Corp. Keytrudas (Pembrolizumab) injection, for Intravenous Use. Whitehouse Station, NJ: Merck Sharp &Dohme Corp.; 2017.
15. Chow LQM, Haddad R, Gupta S, et al. Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: results from the phase Ib KEYNOTE-012 expansion cohort. J Clin Oncol. 2016;34:3838-3845.
16. Seiwert TY, Burtness B, Mehra R, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an openlabel, multicentre, phase 1b trial. Lancet Oncol. 2016;17:956-965.
17. Dolled-Filhart M, Roach C, Toland G, et al. Development of a companion diagnostic for pembrolizumab in non-small cell lung cancer using immunohistochemistry for programmed death ligand-1. Arch Pathol Lab Med. 2016;140:1243-1249.
18. Muro K, Chung HC, Shankaran V, et al. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. Lancet Oncol. 2016;17:717-726.
19. Romeu JL. Understanding binomial sequential testing. Statistical Confidence, Reliability Information Analysis Center (RIAC START). START. Selected Topics in Assurance Related Technologies. 2016;12:1-8.
20. Gilbert J, Li Y, Pinto HA, et al. Phase II trial of taxol in salivary gland malignancies (E1394): a trial of the Eastern Cooperative Oncology Group. Head Neck. 2006;28:197-204.
21. Thomson DJ, Silva P, Denton K, et al. Phase II trial of sorafenib in advanced salivary adenoid cystic carcinoma of the head and neck. Head Neck. 2015;37:182-187.
22. Keam B, Kim SB, Shin SH, et al. Phase 2 study of dovitinib in patients with metastatic or unresectable adenoid cystic carcinoma. Cancer. 2015;121:2612-2617.